Clowse, M. E. B., Scheuerle, A. E., Chambers, C., Afzali, A., Kimball, A., Cush, J. J., … Förger, F. (2018). OP0200 Characteristics and outcomes of prospectively reported pregnancies exposed to certolizumab pegol from a safety database. In THURSDAY, 14 JUNE 2018. BMJ Publishing Group Ltd and European League Against Rheumatism. https://doi.org/10.1136/annrheumdis-2018-eular.2417

Clowse, M. E. B., A. E. Scheuerle, C. Chambers, A. Afzali, A. Kimball, J. J. Cush, M. Cooney, L. Shaughnessy, M. Vanderkelen, and F. Förger. “OP0200 Characteristics and outcomes of prospectively reported pregnancies exposed to certolizumab pegol from a safety database.” In THURSDAY, 14 JUNE 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. https://doi.org/10.1136/annrheumdis-2018-eular.2417.

Clowse MEB, Scheuerle AE, Chambers C, Afzali A, Kimball A, Cush JJ, et al. OP0200 Characteristics and outcomes of prospectively reported pregnancies exposed to certolizumab pegol from a safety database. In: THURSDAY, 14 JUNE 2018. BMJ Publishing Group Ltd and European League Against Rheumatism; 2018.

Clowse, M. E. B., et al. “OP0200 Characteristics and outcomes of prospectively reported pregnancies exposed to certolizumab pegol from a safety database.” THURSDAY, 14 JUNE 2018, BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. Crossref, doi:10.1136/annrheumdis-2018-eular.2417.

Clowse MEB, Scheuerle AE, Chambers C, Afzali A, Kimball A, Cush JJ, Cooney M, Shaughnessy L, Vanderkelen M, Förger F. OP0200 Characteristics and outcomes of prospectively reported pregnancies exposed to certolizumab pegol from a safety database. THURSDAY, 14 JUNE 2018. BMJ Publishing Group Ltd and European League Against Rheumatism; 2018.